1.07
0.07 (7.32%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Bearish | Bearish |
Biotechnology (Global) | Bearish | Bearish | |
Stock | Eyenovia, Inc. | Mixed | - |
Stockmoo Score
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
52 Weeks Range | ||
Median | 12.00 (1,021.50%) | |
Total | 1 Buy |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
HC Wainwright & Co. | 24 Jul 2024 | 12.00 (1,021.50%) | Buy | 1.41 |
16 May 2024 | 12.00 (1,021.50%) | Buy | 0.821 |
No data within this time range.
Date | Type | Details |
---|---|---|
23 Jul 2024 | Announcement | Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease |
01 Jul 2024 | Announcement | NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities |
28 Jun 2024 | Announcement | Eyenovia Announces Pricing of $5M Registered Direct Offering |
15 May 2024 | Announcement | Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol |
14 May 2024 | Announcement | Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |